Related Experiment Video
Updated: Sep 14, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health
Brendan Saloner1, Meredith Matone, Amanda R Kreider
1Dr. Saloner is with the Department of Health Care Policy, Johns Hopkins University, Baltimore (e-mail: bsaloner@gmail.com ). Ms. Matone, Ms. Kreider, Mr. Budeir, Ms. Miller, and Dr. Rubin are with PolicyLab, Children's Hospital of Philadelphia, Philadelphia. Dr. Rubin is also with the Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Ms. Huang is with Division of General Pediatrics and Healthcare Analytics Unit, Children's Hospital of Philadelphia. Dr. Raghavan is with the George Warren Brown School of Social Work, Washington University in St. Louis, St. Louis, Missouri. Dr. French is with the Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia.
Insights
Managed behavioral health carve-outs were linked to lower second-generation antipsychotic use in children. This contrasts with fee-for-service and integrated care models, highlighting service organization
Area of Science:
- Health Services Research
- Pediatric Psychiatry
- Health Policy
Background:
- Overuse of second-generation antipsychotics (SGAs) in children enrolled in Medicaid is a significant concern.
- Understanding how different Medicaid service organization structures impact SGA utilization is crucial for policy development.
- Limited research exists on the comparative effectiveness of fee-for-service, integrated managed care, and managed behavioral health carve-out models in pediatric SGA use.
Purpose of the Study:
- To compare second-generation antipsychotic utilization rates among Medicaid-enrolled children across three distinct service organization structures: fee-for-service, integrated managed care, and managed behavioral health carve-outs.
- To identify which organizational structures are associated with higher or lower rates of antipsychotic prescribing in pediatric populations.
Main Methods:
- Cross-sectional analysis of child-level claims data from the Medicaid Analytic Extract (2004, 2006, 2008) across 82 counties in 34 states.
- Sample restricted to stimulant-using children aged 3-18 (N=419,226) to approximate the population at risk for antipsychotic treatment.
- Logistic regression models estimated SGA use probability, with county-level organizational structure as a primary predictor, adjusting for individual and county covariates.
Main Results:
- Youth in foster care using SGAs were 31% more likely in fee-for-service counties compared to carve-out counties (OR=1.69).
- Foster care youth in integrated managed care counties showed the second-highest adjusted odds of SGA use (OR=1.31).
- Similar patterns were observed for Supplemental Security Income-eligible youth, but not for Temporary Assistance for Needy Families recipients; differences persisted after covariate adjustment.
Conclusions:
- Managed behavioral health carve-outs were associated with significantly lower second-generation antipsychotic use among Medicaid-enrolled children compared to fee-for-service and integrated managed care models.
- Further investigation into specific features of carve-out models, such as enhanced inpatient management or restricted access protocols, is warranted.
- Care coordination mechanisms within carve-out structures may contribute to reduced antipsychotic prescribing, offering potential strategies for optimizing pediatric mental healthcare delivery.
Objective:
Reducing overuse of second-generation antipsychotics among Medicaid-enrolled children is a national priority, yet little is known about how service organization affects use. This study compared differences in second-generation antipsychotic utilization among Medicaid-enrolled children across fee-for-service, integrated managed care, and managed behavioral health carve-out organizational structures.
Methods:
Organizational structures of Medicaid programs in 82 diverse counties in 34 states were categorized and linked to child-level cross-sectional claims data from the Medicaid Analytic Extract covering fiscal years 2004, 2006, and 2008. To approximate the population at risk of antipsychotic treatment, the sample was restricted to stimulant-using children ages three to 18 (N=419,226). The sample was stratified by Medicaid eligibility group, and logistic regression models were estimated for probability of second-generation antipsychotic use. Models included indicators of county-level organizational structure as main predictors, with sequential adjustment for personal and county-level covariates.
Results:
With adjustment for person-level covariates, second-generation antipsychotic use was 31% higher among youths in foster care in fee-for-service counties than for youths in counties with carve-outs (odds ratio [OR]=1.69, 95% confidence interval [CI]=1.26-2.27). Foster care youths in integrated counties had the second highest adjusted odds (OR=1.31, CI=1.08-1.58). Similar patterns of use also were found for youths eligible for Supplemental Security Income but not for those eligible for Temporary Assistance for Needy Families. Differences persisted after adjustment for county-level characteristics.
Conclusions:
Carve-outs, versus other arrangements, were associated with lower second-generation antipsychotic use. Future research should explore carve-out features (for example, tighter management of inpatient or restricted access, as well as care coordination) contributing to lower second-generation antipsychotic use.
More Related Videos
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
07:20Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
Published on: August 9, 2024
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Drug Therapy
Antianxiety Medications
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.